Table 3.

Cancer Treatments by Insurance Status^†

Insurance	Percentage	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Breast Cancer
Receipt of Breast Conserving Surgery*
FFS	40.2	1.00	1.00
HMO	47.2	1.33 (1.13 – 1.58)	0.97 (0.87 – 1.07)
Mixed HMO/FFS	44.9	1.22 (0.75 – 1.96)	1.04 (0.80 – 1.34)
Receipt of Radiation Therapy after Breast Conserving Surgery**
FFS	70.7	1.00	1.00
HMO	79.4	1.60 (1.18 – 2.16)	1.11 (1.03 – 1.19)
Mixed HMO/FFS	83.3	2.07 (0.79 – 5.45)	1.21 (1.06 – 1.39)
Receipt of Lymph Node Dissection***
FFS	86.2	1.00	1.00
HMO	85.0	0.91 (0.72 – 1.15)	1.01 (0.98 – 1.04)
Mixed HMO/FFS	87.0	1.07 (0.53 – 2.17)	1.01 (0.92 – 1.11)
Lung Cancer
Receipt of Surgery****
FFS	63.1	1.00	1.00
HMO	69.3	1.10 (1.01 – 1.20)	1.06 (0.97 – 1.16)
Mixed HMO/FFS	80.0	1.27 (1.04 – 1.54)	1.23 (1.02 – 1.49)
Receipt of Radiation Therapy*****
FFS	28.7	1.00	1.00
HMO	22.9	0.79 (0.63 – 1.00)	0.93 (0.77 – 1.12)
Mixed HMO/FFS	20.0	0.69 (0.31 – 1.53)	1.11 (0.66 – 1.84)
Receipt of Surgery or Radiation Therapy*****
FFS	88.6	1.00	1.00
HMO	88.8	1.00 (0.96 – 1.05)	1.00 (0.95 – 1.05)
Mixed HMO/FFS	96.0	1.09 (1.00 – 1.18)	1.09 (1.02 – 1.17)

^†Insurance status during period including month of diagnosis and 6 months following month of diagnosis.

^*Among women having AJCC stage I or II, or IIIA lesions, and undergoing either BCS or mastectomy (n=4,480)

^**Among women having AJCC stage I or II, or IIIA lesions, and undergoing breast conserving surgery (n=1,775)

^***Among women having AJCC stage I or II, or IIIA lesions (n=4,480)

^****Among persons having AJCC stage I cancers (n=2,240)

^*****Among persons having AJCC stage I cancers (n=2,240). Adjusted models also controlled for concomitant use of lung cancer surgery.

Outcomes in bold are significant at p<0.05